Gene
BCOR
BCOR is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (27), Actionable biomarkers (1), Trial mentions (30), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention BCOR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 7 of 8,875 | 0.08% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 17 of 11,460 | 0.15% |
| 2022 | 3 of 8,285 | 0.04% | 12 of 13,598 | 0.09% |
| 2021 | 5 of 8,692 | 0.06% | 19 of 15,045 | 0.13% |
| 2020 | 1 of 7,640 | 0.01% | 11 of 14,459 | 0.08% |
| 2019 | 0 of 7,300 | 0.00% | 3 of 12,159 | 0.02% |
| 2018 | 2 of 6,927 | 0.03% | 17 of 11,854 | 0.14% |
| 2017 | 1 of 6,558 | 0.02% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Assay-provider ledger (27)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | December 01, 2021 |
| Guang Zhou LBP Medicine Science & Technology Co., Ltd. | Diagnostic provider | Clinical validationAnalytical validation | 1 | June 08, 2021 |
| Clinomics Inc | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 27, 2020 |
| Horizon Discovery | Reagent supplier | Clinical validationAnalytical validation | 1 | July 27, 2020 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 1 | July 27, 2020 |
Showing 5 of 27 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| BCOR oncogenic mutation | Enzastaurin | response-associated | gastric carcinoma | Cancer Genome Interpreter |
Trial mentions (30)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06779435 | Trial eligibility (AACT) |
| NCT04620681 | Trial eligibility (AACT) |
| NCT04659616 | Trial eligibility (AACT) |
| NCT07851636 | Trial eligibility (AACT) |
| NCT07159620 | Trial eligibility (AACT) |
Showing 5 of 30 trial mentions.
Target-disease associations (354)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| Abnormal brain morphology | phenotype | Variant curation (ClinVar / EVA) |
| Abnormal sperm morphology | phenotype | Expression Atlas |
| Abnormality of refraction | phenotype | GWAS credible sets |
| Adamantinomatous Craniopharyngioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 354 associations.
Vendor sourcing (121)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense... | View ClinVar record SCV002521900.1 |
| Adriana Fonseca | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients must have a relapse or recurrence of one of the following rare brain tumors: * CNS sarcoma (e.g. EWS, CIC, DICER1 altered) * BCOR alter... | View trial NCT07851636 |
| Adriana Fonseca | Trial sponsor | Mentioned in trial textTrial free-text mention | BCOR | View trial NCT07851636 |
| Affiliated Hospital of Southwest Medical University | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted without stated criteria (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV002584968.1 |
| Alex's Lemonade Stand Foundation | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | . * Patients with distant metastatic disease. * Patients with known Ewing-like sarcoma (e.g., BCOR-CCNB3 or CIC-DUX4 translocated small round cell sarcomas) ... | View trial NCT06068075 |
Showing 5 of 121 sourcing records.
Trial-cited literature (114)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. | Blood neoplasia | 2026 | 0 |
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). | Leukemia | 2024 | 35 |
| Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. | Blood advances | 2024 | 33 |
Showing 5 of 114 papers.
Protein variant mentions (37)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A161V | 1 | 2015 | PMID 25741868 |
| p.A184V | 1 | 2023 | PMID 36639200 |
| p.A362T | 1 | 2015 | PMID 25741868 |
| p.D1389N | 1 | 2023 | PMID 37533228 |
| p.D1635N | 1 | 2015 | PMID 25741868 |
Showing 5 of 37 variants.
Literature-extracted relations (13)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Leukemia, Myeloid, Acute | Disease | associate |
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. | 2024 |
| Leukemia, Myeloid, Acute | Disease | associate |
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. | 2020 |
| Myelodysplastic Syndromes | Disease | associate |
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. | 2020 |
| Myelodysplastic Syndromes | Disease | associate |
Myelodysplastic syndromes: Contemporary review and how we treat. | 2016 |
| Anemia, Aplastic | Disease | associate |
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. | 2015 |
Showing 5 of 13 relation assertions.
Organizations publishing (252)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2015 to 2021 |
| Government of the United States of America | Government | 8 | 2004 to 2024 |
| Dana-Farber Cancer Institute | Other | 7 | 2015 to 2023 |
| The University of Texas System | Academic | 7 | 2013 to 2026 |
| Harvard Medical School | Academic | 6 | 2013 to 2022 |
Showing 5 of 252 organizations.
Where BCOR appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- measurement
- nervous system disease
- phenotype
316 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.